Clinical trial
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects
NCT02169414 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects
- Lead sponsor
- Bial - Portela C S.A.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2010
- Completion date
- July 31, 2010
- Enrollment
- 74 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
parkinson's disease (pd)